Navigation Links
PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
Date:10/24/2008

ted chloride channel activity as measured by nasal potential difference, with 40 percent of patients achieving values in the normal range during PTC124 administration. The study demonstrated improvements in patients with multiple nonsense mutation types and indicated a similar PTC124 pharmacokinetic profile as that seen in previous studies in adults. PTC124 was generally well tolerated in this study and compliance was greater than or equal to 93 percent.

"We are encouraged by the results of this study showing PTC124 to be as pharmacologically active and well tolerated in children with CF as it is in adults," said Dr. Sermet-Gaudelus. "There is a serious need for new methods to treat the underlying cause of CF, particularly in younger patients who have not yet experienced irreversible disease-related lung injury. These data in pediatric patients support inclusion of children with CF in long-term studies of PTC124."

Israeli Phase 2a 12-Week Study Results

The Phase 2a extension study evaluated 12 weeks of oral PTC124 at two different dose levels in 19 adults with nonsense-mutation CF who participated in a prior short-term PTC124 Phase 2a study. Greater than 85 percent of the patients had chronic CF-related lung infection and pancreatic insufficiency. Study results showed that treatment with PTC124 resulted in statistically significant improvements in CFTR function as measured by nasal potential difference in both dose groups. Improvements in lung function, including forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), were also observed. Baseline data showed that the patients coughed a remarkable 630 times per day on average, with a range of 320 to 1,330 coughs per day, compared to healthy individuals who typically cough fewer than 16 times per day, according to the European Respiratory Journal (Hsu 1994). Patients in this study experienced a mean decrease in cough frequency of almost 200 coughs per day by the end of the s
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
4. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
5. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
6. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
7. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
8. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
9. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
10. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
11. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 Professional ... in paediatric medicine by awarding the three best ... Formulation initiative (EuPFI) conference . The Formulating ... – 18 in Athens, Greece ... pharmacy students and professionals, from which three winners ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal ... PHIA) today announced it has received 510(k) clearance ... market its precision planning application for Transcatheter Aortic-Valve ... TAVI application provides interventionalists with pre-procedural, high-precision positioning ... Philips TAVI planning application is available as part ...
(Date:8/21/2014)... JOSE, Calif. , Aug. 21, 2014  SI-BONE, ... medical device company that pioneered the use of the ... (MIS) device indicated for fusion of the sacroiliac (SI) ... ) published an update to its Lumbar Fusion Medical ... SI joint fusion procedure.  The policy states that the ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... KVM Switches to be First Units to Sport New ... ... ATEN Technology, Inc., an,innovator of high-quality KVM (keyboard/video/mouse) and remote,connectivity ... the first LCD KVM switches to feature,product-protected antimicrobial nanocoating. The ...
... LA JOLLA, Calif., Sept. 10 TorreyPines,Therapeutics, Inc. ... its third,Phase I clinical trial for NGX267, in ... with schizophrenia (CIAS). The,compound, a functionally selective muscarinic ... when given orally to healthy male volunteers,once-daily for ...
Cached Medicine Technology:Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 2Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 3Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 4TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia 2TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia 3
(Date:8/21/2014)... (PRWEB) August 21, 2014 Transvaginal ... Bard, Inc. continue to move forward in the ... Southern District of West Virginia, Bernstein Liebhard LLP ... August 14th, the Court has established new stipulated ... special handling, division, storage and preservation. (In re ...
(Date:8/21/2014)... care physicians in rural communities do not routinely ... to Penn State medical and public health researchers. ... have limited resources if they seek help., "Rural ... women," said Jennifer S. McCall-Hosenfeld, a primary care ... health sciences, Penn State College of Medicine. "However, ...
(Date:8/21/2014)... London, UK (PRWEB) August 21, 2014 ... from USD 15.6 billion in 2014 and reach USD ... during the forecast period. The drivers of such growth ... products, rising obese and diabetic population, and surging ageing ... costs of state-of-the-art wound care products. Region-wise, North America ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Lauren Collura, a ... the 2014 “Back to the Boardwalk” Facebook sweepstakes. Lauren, her ... a beautiful four-bedroom beachfront house in Lavallette beginning this Saturday. ... to the Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue ... communities after Superstorm Sandy and decided to make it a ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- In a ... that pregnant women avoid eating tuna due to concerns ... tuna, which is second only to shrimp as the ... encourage pregnant women to avoid all tuna," Jean Halloran, ... advocacy division of Consumer Reports, said in a news ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2
... Nov. 5 Attorneys from Dallas, Rasansky Law Firm ... court on behalf of the mother of a 2-year-old girl who ... year ago. The lawsuit includes claims that the day care,s owners ... the child,s death from showing up on a state licensing database. ...
... is pleased to announce their standing in the latest ... quick, confidential performance ratings and comparisons of technology vendors, ... overall in their Q3 2009 Customer Satisfaction Industry Report. ... customer satisfaction score was the lowest ever reported by ...
... FRANCISCO, Nov. 5 Quantros, Inc., an industry leader ... point of care data surveillance solutions, today announced the ... ), a publicly traded company spun off from Cardinal ... were not disclosed. , This latest addition to ...
... Investments to ... ... nonprofit venture capital firm that invests in entrepreneurs who are building businesses to serve the ... Hill Eye and Laser Centre (UHEAL) in Kenya, both of which provide advanced eye care ...
... study finds, , THURSDAY, Nov. 5 (HealthDay News) -- What ... a good night,s sleep come more easily. , A study ... the odds of having disturbed sleep in the seven years ... years before they stopped working. , Sleep improvements probably had ...
... , WATSONVILLE, Calif., Nov. 5 Nordic Naturals ... especially for pregnant women to ensure adequate DHA, an ... for the new mother and developing baby. Prenatal DHA ... the leading non-profit organization in the United States that ...
Cached Medicine News:Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:ChemSW Rated Top Vendor Overall for Customer Satisfaction in Q3 2009 by VendorRate 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 3Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 2Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 3Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 4Health News:Without Job Stress, Retirees Sleep Better 2Health News:Nordic Naturals Professional Exclusive Division Introduces Prenatal DHA An Omega-3 Fatty Acid Supplement for Pregnant Women 2
... AST (GOT) powder reagent once reconstituted offers ... liquid stability to help maximize laboratory productivity, ... turnaround time. The patented technology of the ... long shelf life and stability once reconstituted ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: